OS Therapies (OSTX) Competitors $1.53 -0.04 (-2.55%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.53 0.00 (0.00%) As of 04/17/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. CHRS, FTLF, EPRX, EDIT, TIL, NMRA, PROC, FATE, ENTA, and TNXPShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Coherus BioSciences (CHRS), FitLife Brands (FTLF), Eupraxia Pharmaceuticals (EPRX), Editas Medicine (EDIT), Instil Bio (TIL), Neumora Therapeutics (NMRA), Procaps Group (PROC), Fate Therapeutics (FATE), Enanta Pharmaceuticals (ENTA), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Coherus BioSciences FitLife Brands Eupraxia Pharmaceuticals Editas Medicine Instil Bio Neumora Therapeutics Procaps Group Fate Therapeutics Enanta Pharmaceuticals Tonix Pharmaceuticals OS Therapies (NYSE:OSTX) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment. Does the media favor OSTX or CHRS? In the previous week, OS Therapies and OS Therapies both had 4 articles in the media. Coherus BioSciences' average media sentiment score of 0.37 beat OS Therapies' score of 0.00 indicating that Coherus BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OS Therapies 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OSTX or CHRS more profitable? OS Therapies has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% Coherus BioSciences -0.15%N/A -24.44% Does the MarketBeat Community believe in OSTX or CHRS? Coherus BioSciences received 439 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 65.26% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformOS TherapiesOutperform Votes10100.00% Underperform VotesNo VotesCoherus BioSciencesOutperform Votes44965.26% Underperform Votes23934.74% Do institutionals & insiders have more ownership in OSTX or CHRS? 72.8% of Coherus BioSciences shares are held by institutional investors. 13.8% of OS Therapies shares are held by company insiders. Comparatively, 7.6% of Coherus BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, OSTX or CHRS? OS Therapies has higher earnings, but lower revenue than Coherus BioSciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79MN/AN/ACoherus BioSciences$266.96M0.49-$237.89M$0.195.89 Do analysts recommend OSTX or CHRS? OS Therapies presently has a consensus target price of $18.00, indicating a potential upside of 1,076.47%. Coherus BioSciences has a consensus target price of $5.38, indicating a potential upside of 379.91%. Given OS Therapies' stronger consensus rating and higher possible upside, equities research analysts plainly believe OS Therapies is more favorable than Coherus BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryOS Therapies beats Coherus BioSciences on 7 of the 12 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$33.15M$6.45B$5.29B$18.43BDividend YieldN/A3.24%5.12%4.22%P/E RatioN/A6.8821.7131.10Price / SalesN/A231.35379.3926.38Price / CashN/A65.6738.2217.54Price / BookN/A5.916.444.30Net Income-$7.79M$142.72M$3.21B$1.02B7 Day Performance36.61%7.98%5.24%2.90%1 Month Performance-6.13%-13.91%-9.49%-7.77%1 Year PerformanceN/A-9.98%11.01%2.31% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.2985 of 5 stars$1.53-2.5%$18.00+1,076.5%N/A$33.15MN/A0.00N/ACHRSCoherus BioSciences3.619 of 5 stars$0.97+16.6%$5.38+451.5%-47.9%$112.95M$266.96M-12.18330Analyst DowngradeNews CoverageFTLFFitLife Brands4.2379 of 5 stars$12.07+3.3%$20.50+69.8%-9.9%$111.27M$64.47M14.2820Positive NewsGap UpEPRXEupraxia Pharmaceuticals1.7664 of 5 stars$3.10+2.3%$10.50+238.7%+25.4%$111.13MN/A-4.3129EDITEditas Medicine4.0157 of 5 stars$1.32+1.5%$6.83+417.7%-77.1%$110.50M$32.31M-0.52230Analyst RevisionNews CoverageTILInstil Bio2.0767 of 5 stars$16.80+11.8%$114.00+578.6%+45.9%$109.64MN/A-1.45410Positive NewsGap UpNMRANeumora Therapeutics3.1648 of 5 stars$0.67-1.8%$9.29+1,286.3%-93.8%$108.49MN/A-0.36108PROCProcaps GroupN/A$0.95-40.3%N/A-64.6%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeFATEFate Therapeutics3.4978 of 5 stars$0.92-12.8%$5.43+487.3%-78.9%$105.93M$13.63M-0.56550News CoverageENTAEnanta Pharmaceuticals4.0353 of 5 stars$4.93+5.1%$17.25+249.9%-63.6%$105.17M$66.59M-1.00160TNXPTonix Pharmaceuticals2.3207 of 5 stars$16.15-4.3%$585.00+3,522.3%-96.9%$103.93M$10.09M0.0050 Related Companies and Tools Related Companies Coherus BioSciences Competitors FitLife Brands Competitors Eupraxia Pharmaceuticals Competitors Editas Medicine Competitors Instil Bio Competitors Neumora Therapeutics Competitors Procaps Group Competitors Fate Therapeutics Competitors Enanta Pharmaceuticals Competitors Tonix Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
